Plain Language summary for the manuscript: Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

Peeva, Elena; Guttman-Yassky, Emma; Banerjee, Anindita; SINCLAIR, RODNEY; Cox, Lori Ann; Zhu, Linda J.; Zhu, Hua; Vincent, Michael; King, Brett

doi:10.25454/pfizer.figshare.19087508.v1

PZ082-21 Ritle MPLS 1005 WD retreat ext 1 dk38.pdf (137.8 kB)

Plain Language summary for the manuscript: Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

journal contribution

posted on 2022-01-28, 22:53 authored by Elena Peeva, Emma Guttman-Yassky, Anindita Banerjee, RODNEY SINCLAIRRODNEY SINCLAIR, Lori Ann Cox, Linda J. Zhu, Hua Zhu, Michael Vincent, Brett King

This is a plain language summary (PLS) of an article published in a peer-reviewed scientific journal. This PLS is not peer-reviewed. The publisher of the original manuscript was not involved in the preparation of this PLS and has neither reviewed nor approved its content.

Funding

This study was funded by Pfizer. Medical writing support for this plain language summary was provided by Jake Evans, PhD of Engage Scientific Solution, and was funded by Pfizer.

History

Disclaimer

ritlecitinib and brepocitinib are not approved products in the US

Citation

Peeva E, Guttman-Yassky E, Banerjee A, Sinclair R, Cox LA, Zhu L, Zhu H, Vincent M, King B. Maintenance, Withdrawal and Re-treatment with Ritlecitinib and Brepocitinib in Patients with Alopecia Areata in a Single-blind Extension of a Phase 2a Randomized Clinical Trial. . J Am Acad Dermatol. 2021;E-Pub Ahead of Print.